ClinicalTrials.gg
RecruitingNCT07081087Updated Mar 25, 2026

Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

An observational study in Cytopenia and MDS, sponsored by Weizmann Institute of Science. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Weizmann Institute of Science · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Cytopenia with a site in United States — 17 open to participants now, 22 under way, 2 of them phase 3. Cytopenia · United States.

Started
2025
with 3 others
Observational
5 of 51
4 open now
Primary completion
2028-12
later than 10 of 20 live
Registered
49th of 51
by date

Among the 51 studies in Cytopenia with a site in United States, this one is one of 4 that started in 2025, is one of 5 observational ones, reaches primary completion later than 10 of the 20 other live ones, and was the 49th registered.

Cytopenia

81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.

Browse Cytopenia studies →

Open to participants now

17 of the 51 studies in Cytopenia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Cytopenia studies recruiting now, 17 (85%) set no upper age limit and 1 (5%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Cytopenia with a site in United States, or all of them as a file.
02

Study summary

This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.

Read the detailed description

This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing. Current MDS diagnosis relies on bone marrow (BM) aspiration and biopsy, which is invasive, technically challenging, and sometimes inconclusive, particularly in early or low-risk disease. Our prior research established a healthy reference map of cHSPC subtypes and developed a computational pipeline that distinguishes MDS from non-clonal cytopenias based on deviations from this reference. In this study, patients referred, as part of standard care, for BM evaluation due to unexplained cytopenias or abnormal blood counts and undergo PB collection for genomic profiling. The study's primary objective is to develop a PB-based test by comparing the developed test diagnoses to the conventional BM-based one. Secondary objectives include evaluating its potential for MDS risk stratification and assessing its ability to reduce the need for BM evaluations.

03

Conditions studied

  • Cytopenia
  • MDS

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with cytopenia, who are referred to BM from the primary care clinic will be recruited to the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 and up with suspected/confirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia
  2. \< 150 × 10E9/L or
  3. \< 1.8 × 10E9/L or
  4. (Hgb) \< 13 g/dL (males) and \< 12 g/dL (female) and
  5. For both sexes, no evidence of Iron, folinic acid, or B12 deficiency

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant
  2. Previous diagnosis of leukemia; AML, MPN, ALL, CLL, MGUS/MM or any other gammopathy
  3. Lymphocytes > 5000/ul
  4. Patients who are on disease-related therapy are excluded, unless they are treated with Erythropoietin or Prednisone. See Appendix 2 for the list of excluded treatments.
  5. Patients who have undergone a bone marrow transplant.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • PERIBLOOD-MDS

    No intervention is given

    Diagnostic Test: PERIBLOOD-MDS

Interventions

  • Diagnostic testPERIBLOOD-MDS

    In the study, peripheral blood will be taken from all patients, shipped and analyzed at the Weizmann Institute of Science to produce a report based on our technology. The report will contain data on the diagnosis, blast counts and karyotype. This information will be compared with the results from the bone marrow scan, taken separately to each patient, to validate the accuracy of our technology

06

What researchers measure

Primary outcomes

  1. To develop PERIBLOOD-MDS diagnostic test of PB cHPCs for the diagnosis of MDS

    Comparison between PERIBLOOD-MDS diagnosis and bone marrow evaluation of MDS

    Time frame: Three months following the peripheral blood sample

07

Study locations

2 of 2 sites recruiting
  • University of California San Diego
    San Diego, California 92093, United States
    Recruiting
    • Tan Tuyet · Contact
    • Rafael Bejar · Principal investigator
  • University of Miami
    Miami, Florida 33146, United States
    Recruiting
    • Helen Kattoura, Dr. · Contact305-243-6438
    • Stephen Nimer · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 23, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07081087
Lead sponsor
Weizmann Institute of Science
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Jun 1, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 25, 2026

Study contacts

Clinical Trial Manage
Contact
gil.gonen-yaacovi@weizmann.ac.il
+972522666230
Liran Shlush, Prof.
Contact
liran.shlush@weizmann.ac.il
+972505109815
Liran Shlush
principal investigator · The Weizmann Institute of Science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion